Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance.
Besides I47A, mutation L76V at the HIV protease gene has recently been proposed to cause lopinavir resistance. This change was present in 37 (2.7%) out of 1376 patients failing protease inhibitor containing regimens. Although 26 (70%) were on lopinavir, most had previously failed other protease inhibitors and carried multiple protease inhibitor resistance mutations. Therefore, L76V does not appear to be a primary lopinavir resistance change when the drug is used in combination therapy.
de Mendoza
Carmen
C
Department of Infectious Diseases, Hospital Carlos III, Madrid, Spain.
Garrido
Carolina
C
Corral
Angélica
A
Zahonero
Natalia
N
Soriano
Vincent
V
D023241:Antiretroviral Therapy, Highly Active; D003062:Codon / Q000235:genetics; D024921:Drug Resistance, Multiple, Viral / Q000235:genetics; D015658:HIV Infections / Q000188:drug therapy / Q000821:virology*; D016333:HIV Protease / Q000187:drug effects / Q000235:genetics*; D017320:HIV Protease Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D061466:Lopinavir; D017354:Point Mutation; D011744:Pyrimidinones / Q000494:pharmacology*; D013030:Spain
D003062:Codon; D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D016333:HIV Protease